BioSpace News Archive

Denali Therapeutics Inc. today announced program progress and expected milestones for 2023, which Chief Executive Officer, Ryan Watts, Ph.D., will highlight during a corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10th, at 10:30 a.m. Pacific Time.

IntelGenx Technologies Corp. announced that its wholly-owned subsidiary, IntelGenx Corp., has received a fourth and final term loan tranche in the amount of U.S.$3 million pursuant to its amended and restated secured loan agreement with atai Life Sciences.

Trinity Biotech today announced a strategic partnership with imaware Inc that combines their built-to-partner digital health platform with Trinity Biotech’s advanced reference laboratory facilities to power the Digital Health Industry with at-home and remote testing programs.

Sensus Healthcare, Inc. is pleased to announce the following promotions and appointments to its management team.

Premier Research and Centogene N.V. have announced a strategic partnership to provide end-to-end support in rare disease clinical trials.

Theralink Technologies today announced the appointment of Michael Vallone as Senior Director of Commercialization.

Lydus Medical is pleased to announce that the Vesseal™ has received FDA clearance 510(k).

Avenge Bio, Inc. (“Avenge”), an oncology-focused biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced dosing of the first patient in a First-in-Human Phase 1/2 clinical trial evaluating AVB-001 in relapsed refractory ovarian cancer.

NeuroDerm Ltd. today announced highly positive results from the Phase III multi-center, randomized, double-blind double-dummy (DBDD) BouNDless trial.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2022 total revenue and U.S.